FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801682062> ?p ?o ?g. }

• W2801682062 endingPage "236" @default.
• W2801682062 startingPage "231" @default.
• W2801682062 abstract "Objective To evaluate the association between furosemide exposure and patent ductus arteriosus (PDA) in a large, contemporary cohort of hospitalized infants with very low birth weight (VLBW). Study design Using the Pediatrix Medical Group Clinical Data Warehouse, we identified all inborn infants of VLBW <37 weeks of gestation discharged from the neonatal intensive care unit after the first postnatal week from 2011 to 2015. We defined PDA as any medical (ibuprofen or indomethacin) or surgical PDA therapy. We collected data up to the day of PDA treatment or postnatal day 18 for infants not diagnosed with PDA. We performed multivariable logistic regression to evaluate the association between PDA and exposure to furosemide. Results We included 43 576 infants from 337 neonatal intensive care units, of whom 6675 (15%) underwent PDA treatment. Infants with PDA were more premature and more often exposed to mechanical ventilation and inotropes. Furosemide was prescribed to 4055 (9%) infants. On multivariable regression, exposure to furosemide was associated with decreased odds of PDA treatment (OR 0.72; 95% CI 0.65-0.79). Increasing percentage of days with furosemide exposure was not associated with PDA treatment (OR 1.01; 95% CI 0.97-1.06). Conclusions Furosemide exposure was not associated with increased odds of PDA treatment in hospitalized infants of VLBW. Further studies are needed to characterize the efficacy and safety of furosemide in premature infants. To evaluate the association between furosemide exposure and patent ductus arteriosus (PDA) in a large, contemporary cohort of hospitalized infants with very low birth weight (VLBW). Using the Pediatrix Medical Group Clinical Data Warehouse, we identified all inborn infants of VLBW <37 weeks of gestation discharged from the neonatal intensive care unit after the first postnatal week from 2011 to 2015. We defined PDA as any medical (ibuprofen or indomethacin) or surgical PDA therapy. We collected data up to the day of PDA treatment or postnatal day 18 for infants not diagnosed with PDA. We performed multivariable logistic regression to evaluate the association between PDA and exposure to furosemide. We included 43 576 infants from 337 neonatal intensive care units, of whom 6675 (15%) underwent PDA treatment. Infants with PDA were more premature and more often exposed to mechanical ventilation and inotropes. Furosemide was prescribed to 4055 (9%) infants. On multivariable regression, exposure to furosemide was associated with decreased odds of PDA treatment (OR 0.72; 95% CI 0.65-0.79). Increasing percentage of days with furosemide exposure was not associated with PDA treatment (OR 1.01; 95% CI 0.97-1.06). Furosemide exposure was not associated with increased odds of PDA treatment in hospitalized infants of VLBW. Further studies are needed to characterize the efficacy and safety of furosemide in premature infants." @default.
• W2801682062 created "2018-05-17" @default.
• W2801682062 creator A5008852386 @default.
• W2801682062 creator A5013471768 @default.
• W2801682062 creator A5026493300 @default.
• W2801682062 creator A5032915456 @default.
• W2801682062 creator A5036387079 @default.
• W2801682062 creator A5046046756 @default.
• W2801682062 creator A5052097658 @default.
• W2801682062 creator A5061796750 @default.
• W2801682062 creator A5067695269 @default.
• W2801682062 creator A5070505630 @default.
• W2801682062 creator A5081987147 @default.
• W2801682062 creator A5085031950 @default.
• W2801682062 date "2018-08-01" @default.
• W2801682062 modified "2023-10-15" @default.
• W2801682062 title "Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight" @default.
• W2801682062 cites W1857797615 @default.
• W2801682062 cites W1884310859 @default.
• W2801682062 cites W1924984470 @default.
• W2801682062 cites W1968285472 @default.
• W2801682062 cites W1980673285 @default.
• W2801682062 cites W1986775615 @default.
• W2801682062 cites W2005654864 @default.
• W2801682062 cites W2008339641 @default.
• W2801682062 cites W2010267035 @default.
• W2801682062 cites W2031480926 @default.
• W2801682062 cites W2033829367 @default.
• W2801682062 cites W2065500254 @default.
• W2801682062 cites W2067170495 @default.
• W2801682062 cites W2079030680 @default.
• W2801682062 cites W2104076287 @default.
• W2801682062 cites W2139774634 @default.
• W2801682062 cites W2154099365 @default.
• W2801682062 cites W2155957464 @default.
• W2801682062 cites W2158228392 @default.
• W2801682062 cites W2172485419 @default.
• W2801682062 cites W2190836993 @default.
• W2801682062 cites W2340304935 @default.
• W2801682062 cites W2554730658 @default.
• W2801682062 cites W2664328585 @default.
• W2801682062 cites W4302387489 @default.
• W2801682062 doi "https://doi.org/10.1016/j.jpeds.2018.03.067" @default.
• W2801682062 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6063759" @default.
• W2801682062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29752171" @default.
• W2801682062 hasPublicationYear "2018" @default.
• W2801682062 type Work @default.
• W2801682062 sameAs 2801682062 @default.
• W2801682062 citedByCount "20" @default.
• W2801682062 countsByYear W28016820622019 @default.
• W2801682062 countsByYear W28016820622020 @default.
• W2801682062 countsByYear W28016820622021 @default.
• W2801682062 countsByYear W28016820622022 @default.
• W2801682062 crossrefType "journal-article" @default.
• W2801682062 hasAuthorship W2801682062A5008852386 @default.
• W2801682062 hasAuthorship W2801682062A5013471768 @default.
• W2801682062 hasAuthorship W2801682062A5026493300 @default.
• W2801682062 hasAuthorship W2801682062A5032915456 @default.
• W2801682062 hasAuthorship W2801682062A5036387079 @default.
• W2801682062 hasAuthorship W2801682062A5046046756 @default.
• W2801682062 hasAuthorship W2801682062A5052097658 @default.
• W2801682062 hasAuthorship W2801682062A5061796750 @default.
• W2801682062 hasAuthorship W2801682062A5067695269 @default.
• W2801682062 hasAuthorship W2801682062A5070505630 @default.
• W2801682062 hasAuthorship W2801682062A5081987147 @default.
• W2801682062 hasAuthorship W2801682062A5085031950 @default.
• W2801682062 hasBestOaLocation W28016820621 @default.
• W2801682062 hasConcept C126322002 @default.
• W2801682062 hasConcept C156957248 @default.
• W2801682062 hasConcept C187212893 @default.
• W2801682062 hasConcept C2777091541 @default.
• W2801682062 hasConcept C2777955127 @default.
• W2801682062 hasConcept C2778376644 @default.
• W2801682062 hasConcept C2778721537 @default.
• W2801682062 hasConcept C2779083892 @default.
• W2801682062 hasConcept C2779234561 @default.
• W2801682062 hasConcept C2781236024 @default.
• W2801682062 hasConcept C54355233 @default.
• W2801682062 hasConcept C66322754 @default.
• W2801682062 hasConcept C71924100 @default.
• W2801682062 hasConcept C72563966 @default.
• W2801682062 hasConcept C86803240 @default.
• W2801682062 hasConceptScore W2801682062C126322002 @default.
• W2801682062 hasConceptScore W2801682062C156957248 @default.
• W2801682062 hasConceptScore W2801682062C187212893 @default.
• W2801682062 hasConceptScore W2801682062C2777091541 @default.
• W2801682062 hasConceptScore W2801682062C2777955127 @default.
• W2801682062 hasConceptScore W2801682062C2778376644 @default.
• W2801682062 hasConceptScore W2801682062C2778721537 @default.
• W2801682062 hasConceptScore W2801682062C2779083892 @default.
• W2801682062 hasConceptScore W2801682062C2779234561 @default.
• W2801682062 hasConceptScore W2801682062C2781236024 @default.
• W2801682062 hasConceptScore W2801682062C54355233 @default.
• W2801682062 hasConceptScore W2801682062C66322754 @default.
• W2801682062 hasConceptScore W2801682062C71924100 @default.
• W2801682062 hasConceptScore W2801682062C72563966 @default.
• W2801682062 hasConceptScore W2801682062C86803240 @default.
• W2801682062 hasFunder F4320332161 @default.

• next